Critical Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The company owns rights to the asthma drug ZYFLO, or zileuton tablets, in addition to other formulations of zileuton throughout the world. ZYFLO is one of the only five lipoxygenase inhibitors approved for marketing by the Untied States Food and Drug Administration and is indicated for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. Critical Therapeutics s commercialization effort for ZYFLO is done with nearly 80 people on the company s specialty sales force. Headquartered in Lexington, Mass., Critical Therapeutics is a privately owned company.